NP-1031

NP-1031

Clinical data
Other names	NP1031
Routes of administration	Unspecified[1]
Drug class	Oxytocin receptor modulator

NP-1031 is an oxytocin receptor modulator which is under development for the treatment of Prader–Willi syndrome.^[1] Its route of administration has not been specified.^[1] The drug has been described as an "obesity therapy".^[1] Deficient oxytocin system signaling may be present in Prader–Willi syndrome and may contribute to behavioral features such as hyperphagia and behavioral difficulties, although more research is needed in this area.^[2][3][4] NP-1031 is being developed by Novel Pharma in South Korea.^[1] As of March 2025, the drug is in the research stage of development.^[1] The chemical structure of NP-1031, and whether it is a small molecule or a peptide, do not yet appear to have been disclosed.^[1]

See also

• Oxytocin receptor agonist
• KNX-100 and LIT-001

References

1. "NP 1031". AdisInsight. 28 March 2025. Retrieved 13 January 2026.
2. Josselsohn A, Zhao Y, Espinoza D, Hollander E (December 2024). "Oxytocin in neurodevelopmental disorders: Autism spectrum disorder and Prader-Willi syndrome". Pharmacology & Therapeutics. 264 108734. doi:10.1016/j.pharmthera.2024.108734. PMC 12329755. PMID 39455012. PWS is a rare neurodevelopmental genetic disorder, affecting 1 in 15,000 births. It is associated with genetic changes on chromosome 15q11-q13 [...] The core symptoms of PWS include hyperphagia, severe rigidity, hypotonia, developmental delays, cognitive deficits, and behavioral problems (Hollander et al., 2021). Oxytocin is a neuropeptide secreted by the hypothalamic paraventricular and supraoptic nuclei and individuals with PWS have a dysfunctional oxytocin system with less oxytocin-producing neurons in the paraventricular nuclei (PVN) and diminished function of the oxytocin receptor gene, subsequently affecting satiety response. In adults with PWS the number of oxytocin-expressing neurons in the PVN is abnormally low, and plasma oxytocin levels are sometimes low relative to their obesity, [...] It has been proposed that in PWS there may be a resistance to oxytocin or overproduction of the non-biologically active form of oxytocin leading to a compensatory decreased expression of oxytocin receptors in the PVN. [...] As such there may be an improvement in satiety and hyperphagia for PWS who supplement with the active formulation of oxytocin. Children with PWS have been found to have social deficits in recognizing facial emotions, cooperation, symbolic play, and parent and peer interactions (Oztan et al., 2022). Oxytocin, when administered to neurotypical individuals has improved recognition of emotions, faces, and increased likelihood of recall of positive social information (Fischer-Shofty et al., 2010; Guastella et al., 2008; Rimmele et al., 2009), promoted trust and reduction in fear of social betrayal (Baumgartner et al., 2008; Kosfeld et al., 2005), and enhanced buffering effect of social support on responsiveness to stress (Heinrichs et al., 2003; Meinlschmidt & Heim, 2007). Thereby, it can be hypothesized that there may be therapeutic benefit of oxytocin on social deficits in PWS as well. [...]
3. Oztan O, Zyga O, Stafford DE, Parker KJ (November 2022). "Linking oxytocin and arginine vasopressin signaling abnormalities to social behavior impairments in Prader-Willi syndrome". Neuroscience and Biobehavioral Reviews. 142 104870. doi:10.1016/j.neubiorev.2022.104870. PMC 11024898. PMID 36113782.
4. Althammer F, Muscatelli F, Grinevich V, Schaaf CP (August 2022). "Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies". Translational Psychiatry. 12 (1) 318. doi:10.1038/s41398-022-02054-1. PMC 9360032. PMID 35941105.

External links

• Our Pipeline - Novel Pharma